Filtros de búsqueda

Lista de obras de Josep Tabernero Caturla

2399 Impact of KRAS mutations on clinical outcomes in advanced refractory pancreatic cancer patients

3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial

artículo científico publicado en 2018

3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT

scientific article published on 01 December 2019

A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effect

artículo científico publicado en 2014

A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors

artículo científico publicado en 2016

A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer

artículo científico publicado en 2017

A Phase I First-in-Human Pharmacokinetic and Pharmacodynamic Study of Serdemetan in Patients with Advanced Solid Tumors

artículo científico publicado en 2011

A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations

scientific article published on 11 February 2019

A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer

artículo científico publicado en 2017

A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS

artículo científico publicado en 2017

A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer

artículo científico publicado en 2015

A catalyst for change: the European cancer Patient's Bill of Rights

artículo científico publicado en 2014

A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction

artículo científico publicado en 2012

A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer

artículo científico publicado en 2004

A personalized preclinical model to evaluate the metastatic potential of patient-derived colon cancer initiating cells

artículo científico publicado en 2013

A pharmacodynamic/pharmacokinetic study of ficlatuzumab in patients with advanced solid tumors and liver metastases

artículo científico publicado en 2014

A phase I dose-escalating study of ES-285, a marine sphingolipid-derived compound, with repeat dose administration in patients with advanced solid tumors

artículo científico publicado en 2010

A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer

artículo científico publicado en 2017

A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors.

artículo científico publicado en 2011

A phase I pharmacokinetic study of PM00104 (Zalypsis) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors

artículo científico publicado en 2013

A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer.

artículo científico publicado en 2011

A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3.

artículo científico publicado en 2015

A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors

artículo científico publicado en 2014

A phase III randomized trial of cyclophosphamide, mitoxantrone, and 5-fluorouracil (CNF) versus cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer

artículo científico publicado en 1995

A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors

artículo científico publicado en 2014

A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma

artículo científico publicado en 2013

A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer

artículo científico publicado en 2013

A shining light in the darkness for the treatment of pancreatic neuroendocrine tumors

artículo científico

Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients withKRASwild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial

artículo científico publicado en 2014

Accomplishments in 2008 in the treatment of advanced metastatic colorectal cancer.

artículo científico publicado en 2009

Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen

artículo científico publicado en 2012

Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients.

artículo científico publicado en 2016

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study

artículo científico publicado en 2015

Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuva

artículo científico publicado en 2012

Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration?

artículo científico publicado en 2008

Advances in targeted therapies for metastatic colorectal cancer

Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Comple

artículo científico publicado en 2016

Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial

artículo científico publicado en 2013

Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW.

artículo científico publicado en 2017

Alpha-fetoprotein-concanavalin a binding as a marker to discriminate between germ cell tumours and liver diseases

artículo científico publicado en 1995

An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer.

artículo científico publicado en 2014

Analysis of Angiogenesis Biomarkers for Ramucirumab Efficacy in Patients with Metastatic Colorectal Cancer from RAISE, a Global, Randomized, Double-Blind, Phase III Study

artículo científico publicado en 2017

Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer.

artículo científico publicado en 2017

Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial

artículo científico

Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis

artículo científico publicado en 2010

Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment.

artículo científico publicado en 2009

Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab

artículo científico publicado en 2014

Application of Monoclonal Antibodies as Cancer Therapy in Solid Tumors ⬇️

artículo científico publicado el 1 de mayo de 2012

Applying the ESMO-Magnitude of Clinical Benefit Scale in real life.

artículo científico publicado en 2016

Aprataxin tumor levels predict response of colorectal cancer patients to irinotecan-based treatment.

artículo científico

Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status

artículo científico publicado en 2017

Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyses of the RAISE trial and validation in an electronic medical record d

artículo científico publicado en 2018

Aurora Kinases: A New Target for Anticancer Drug Development

article

Aurora kinase family: a new target for anticancer drug.

scientific article published on June 2008

Author Correction: Caring for patients with cancer in the COVID-19 era

scientific article published on 03 June 2020

Awareness, Understanding, and Adoption of Precision Medicine to Deliver Personalized Treatment for Patients With Cancer: A Multinational Survey Comparison of Physicians and Patients

artículo científico publicado en 2016

BOMP/EPI intensive alternating chemotherapy for IGCCC poor-prognosis germ-cell tumors: The Spanish Germ-Cell Cancer Group experience (GG)

article

BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives

artículo científico publicado en 2017

BRAF-mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer

scientific article published on 11 February 2020

Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial

artículo científico publicado en 2017

Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial

artículo científico publicado en 2012

Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab

artículo científico publicado en 2016

Biomarker-driven patient selection for early clinical trials

artículo científico

Biomarkers for Therapies Directed at Angiogenesis

Biomarkers in colorectal cancer

artículo científico publicado en 2010

Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers

artículo científico publicado en 2016

Brexit: a European perspective.

artículo científico publicado en 2016

Brush border myosin Ia has tumor suppressor activity in the intestine.

artículo científico publicado en 2012

CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer

artículo científico publicado en 2016

CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity

artículo científico publicado en 2008

Cancer Core Europe: A translational research infrastructure for a European mission on cancer

Cancer Core Europe: a consortium to address the cancer care-cancer research continuum challenge

artículo científico publicado en 2014

Cancer Genome Interpreter Annotates The Biological And Clinical Relevance Of Tumor Alterations

artículo científico publicado en 2017

Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations

artículo científico publicado en 2018

Cancer: A precision approach to tumour treatment

artículo científico publicado en 2017

Cancer: Pinprick diagnostics.

artículo científico publicado en 2012

Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial

artículo científico publicado en 2015

Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer.

artículo científico publicado en 2011

Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria

scientific article published on 22 November 2019

Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.

artículo científico

Carcinoembryonic Antigen Levels and Survival in Stage III Colon Cancer: Post hoc Analysis of the MOSAIC and PETACC-8 Trials

scientific article published on 01 July 2019

Cardiotoxicity

artículo científico publicado en 2010

Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO).

artículo científico publicado en 2016

Caring for patients with cancer in the COVID-19 era

scientific article published on 16 April 2020

Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study

artículo científico publicado en 2014

Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis

artículo científico

Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma.

artículo científico publicado en 2015

Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study.

artículo científico publicado en 2009

Cetuximab and Chemotherapy for Patients with Unresectable CRC Liver Metastasis: Are We Changing the Natural Course of the Disease?

artículo científico publicado en 2007

Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer.

artículo científico publicado en 2008

Changing the paradigm in conducting randomized clinical studies in advanced pancreatic cancer: an opportunity for better clinical development

artículo científico publicado en 2009

Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors

artículo científico publicado en 2007

Chop Chemotherapy of Intermediate and High-Grade Non-Hodgkin's Lymphoma

artículo científico publicado en 1994

Circulating pEGFR is a candidate response biomarker of cetuximab therapy in colorectal cancer

artículo científico publicado en 2014

Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.

artículo científico publicado en 2012

Circulating tumour cells and cell-free DNA as tools for managing breast cancer

artículo científico

Circulating tumour cells in early breast cancer

Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms

artículo científico publicado en 2008

Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trial

artículo científico publicado en 2011

Clinical and molecular characterization of refractory BRAF mutant metastatic colorectal carcinoma (mCRC): Vall d’Hebron Institute of Oncology phase I program cohort

Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients

artículo científico publicado en 2020

Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab

artículo científico publicado en 2014

Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies

artículo científico publicado en 2017

Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition

artículo científico publicado en 2013

Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study

artículo científico publicado en 2008

Combined Antiangiogenesis and Antiepidermal Growth Factor Receptor Targeting in the Treatment of Cancer: Hold Back, We Are Not There Yet

artículo científico publicado en 2007

Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.

artículo científico publicado en 2004

Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer

artículo científico publicado en 2017

Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer

artículo científico publicado en 2017

Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer

artículo científico publicado en 2017

Consensus on the treatment of pancreatic cancer in Spain.

artículo científico publicado en 2009

Constitutive HER2 signaling promotes breast cancer metastasis through cellular senescence.

artículo científico publicado en 2013

Control of carcinoid syndrome with everolimus

artículo científico publicado en 2011

Core business, future direction, and the 10-bar target

artículo científico publicado en 2014

Correction to Lancet Oncol 2015; 16: 499-508. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a

artículo científico publicado en 2015

Correction to: A Phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients

artículo científico publicado en 2017

Corrigendum: A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effect

artículo científico publicado en 2016

Corrigendum: Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges

artículo científico publicado en 2018

Corrigendum: mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer

artículo científico publicado en 2018

Current and advancing treatments for metastatic colorectal cancer

artículo científico publicado en 2015

Current issues in adjuvant treatment of stage II colon cancer

artículo científico publicado en 2006

Cyclin E amplification/overexpression is associated with poor prognosis in gastric cancer

scientific article published on 17 November 2014

DPYD genotype-guided fluoropyrimidines dose: is it ready for prime time?

artículo científico publicado en 2017

Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial.

artículo científico publicado en 2016

Depicting the evolving scenario of translational-guided drug development

article

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

artículo científico publicado en 2010

Design and conduct of early clinical studies of immunotherapy: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies 2019 (MDICT)

artículo científico publicado en 2020

Detailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) threshold rules.

artículo científico publicado en 2017

Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma.

artículo científico publicado en 2015

Development of PI3K inhibitors: lessons learned from early clinical trials

artículo científico

Development of molecular biomarkers in individualized treatment of colorectal cancer

artículo científico publicado en 2011

Development of new drug strategies in infrequent digestive tumors: esophageal, biliary tract, and anal cancers.

artículo científico publicado en 2009

Diagnosis and treatment of hepatocellular carcinoma

artículo científico publicado en 2009

Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH

artículo científico publicado en 2016

Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study.

artículo científico

Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group

artículo científico publicado en 2007

Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.

artículo científico publicado en 2008

Dose-Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study

article

Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer

artículo científico publicado en 2011

Drugs in clinical trials

Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy

artículo científico publicado en 2012

EGFR and KRAS in colorectal cancer

artículo científico publicado en 2010

ERRATUM: Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity

artículo científico publicado en 2015

ESICM LIVES 2016: part two

article

ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers

artículo científico publicado en 2016

ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016

artículo científico publicado en 2016

ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

artículo científico publicado en 2012

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.

artículo científico publicado en 2016

Effect of trifluridine/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis

artículo científico publicado en 2020

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

artículo científico publicado en 2010

Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials

artículo científico publicado en 2013

Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results

artículo científico publicado en 2005

Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial

scientific article published on 21 July 2016

Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory ly

artículo científico publicado en 2014

Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: comparative outcomes from the 03-TTD-01 phase III study.

artículo científico publicado en 2008

Emerging strategies in the treatment of advanced esophageal, gastroesophageal junction, and gastric cancer: the introduction of targeted therapies

Emerging trends in combinations of gefitinib and cytotoxic agents: new opportunities

artículo científico publicado en 2005

Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer

artículo científico publicado en 2016

Enhancing the Biological Relevance of Secretome-Based Proteomics by Linking Tumor Cell Proliferation and Protein Secretion

artículo científico publicado en 2014

Epidermal growth factor receptor (EGFR) inhibitors in gastrointestinal cancer.

artículo científico publicado en 2006

Epigenetic EGFR Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas

scientific article published on 31 October 2019

Epigenetic Homogeneity Within Colorectal Tumors Predicts Shorter Relapse-Free and Overall Survival Times for Patients With Locoregional Cancer

artículo científico publicado en 2016

Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer.

artículo científico publicado en 2013

Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis

artículo científico publicado en 2016

Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068.

artículo científico publicado en 2013

Evaluation of aflibercept in the treatment of metastatic colorectal cancer

artículo científico publicado en 2014

Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer

artículo científico publicado en 2017

Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial

artículo científico publicado en 2017

Fe de errores a «Recomendaciones para la determinación de mutaciones de K-RAS en cáncer de colon»

Feasibility of CT scan-guided Tru-Cut serial liver biopsies to evaluate pharmacodynamic endpoints in patients with liver metastasis treated with experimental drugs

artículo científico publicado en 2004

Feasibility of cetuximab given with a simplified schedule every 2 weeks in advanced colorectal cancer: a multicenter, retrospective analysis

artículo científico publicado en 2010

Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors

artículo científico publicado en 2015

Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer

artículo científico publicado en 2014

First-Line Treatment of Metastatic Colorectal Cancer: Interpreting FIRE-3, PEAK, and CALGB/SWOG 80405.

artículo científico publicado en 2015

First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer.

artículo científico publicado en 2015

First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors.

artículo científico

First-in-human phase I study of Lurbinectedin (PM01183) in patients with advanced solid tumors

artículo científico publicado en 2014

First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement

artículo científico publicado en 2013

First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours

artículo científico publicado en 2012

First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study

artículo científico publicado en 2012

GDF15 Is an Eribulin Response Biomarker also Required for Survival of DTP Breast Cancer Cells

scientific article published on 23 May 2022

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer

artículo científico publicado en 2018

Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis

artículo científico publicado en 2012

Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets

artículo científico publicado en 2015

Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors

artículo científico publicado en 2014

Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity

artículo científico publicado en 2013

Genomic analysis identifies association of Fusobacterium with colorectal carcinoma

artículo científico publicado en 2012

Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial

artículo científico publicado en 2019

Genomic classifier ColoPrint predicts recurrence in stage II colorectal cancer patients more accurately than clinical factors

artículo científico publicado en 2015

Genomic medicine frontier in human solid tumors: prospects and challenges

artículo científico

Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion

artículo científico publicado en 2011

Global cancer control: responding to the growing burden, rising costs and inequalities in access.

artículo científico publicado en 2018

Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials).

artículo científico publicado en 2014

Guides for adjuvant treatment of colon cancer. TTD Group (Spanish Cooperative Group for Gastrointestinal Tumor Therapy).

artículo científico publicado en 2006

HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric o

artículo científico publicado en 2017

HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab

artículo científico publicado en 2013

Handling side-effects of targeted therapies: safety of targeted therapies in solid tumours

scientific article published on 01 September 2008

Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGS

artículo científico publicado en 2020

Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial

artículo científico publicado en 2019

Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment

scientific article published on 08 March 2021

Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy

artículo científico publicado en 2018

Immunomodulatory effects in a phase II study of lenalidomide combined with cetuximab in refractory KRAS-mutant metastatic colorectal cancer patients

artículo científico publicado en 2013

Immunotherapy for Gastric Cancer: A Focus on Immune Checkpoints.

artículo científico publicado en 2016

Impact of Prior Bevacizumab Treatment on VEGF-A and PlGF Levels and Outcome Following Second-Line Aflibercept Treatment: Biomarker Post Hoc Analysis of the VELOUR Trial

artículo científico publicado en 2019

Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer

artículo científico publicado en 2015

Impact of glucose-lowering agents on the risk of cancer in type 2 diabetic patients. The Barcelona case-control study

artículo científico publicado en 2013

Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial

artículo científico publicado en 2009

Improving outcomes in colorectal cancer: where do we go from here?

artículo científico

Improving the Armamentarium of PI3K Inhibitors with Isoform-Selective Agents: A New Light in the Darkness

artículo científico publicado en 2017

Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review

artículo científico publicado en 2017

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

artículo científico publicado en 2013

Integrated genomic analysis of colorectal cancer progression reveals activation of EGFR through demethylation of the EREG promoter

artículo científico publicado en 2016

Integration of anti-epidermal growth factor receptor therapies with cytotoxic chemotherapy

artículo científico publicado en 2010

Intrinsic cancer subtypes-next steps into personalized medicine

Irreversible pan-ErbB tyrosine kinase inhibitor CI-1033 induces caspase-independent apoptosis in colorectal cancer DiFi cell line

artículo científico publicado en 2005

K-Ras mutation status as a predictive biomarker in metastatic colorectal cancer

artículo científico publicado en 2008

Knowledge and use of biosimilars in oncology: a survey by the European Society for Medical Oncology

LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy

scientific article published on 11 June 2019

Lack of Efficacy of Streptozocin and Doxorubicin in Patients With Advanced Pancreatic Endocrine Tumors

scientific article published on 01 August 2005

Letter to the editor regarding the paper by A. Lozano-Blázquez et al. Differences in cancer drug assessment between Spain and the United Kingdom.

artículo científico publicado en 2016

Light and shade of intrahepatic arterial radiotherapy in mCRC

artículo científico publicado en 2016

Liquid biopsy detects early molecular response and predicts benefit to first-line chemotherapy plus cetuximab in metastatic colorectal cancer: PLATFORM-B study

artículo científico publicado en 2022

MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.

scientific article published on 13 August 2015

MODUL-a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach

artículo científico publicado en 2018

Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer

artículo científico publicado en 2013

Mediastinal non-seminomatous germ cell tumours (MNSGCT) treated with cisplatin-based combination chemotherapy

artículo científico publicado en 1997

Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab

artículo científico publicado en 2017

Methodological aspects of the molecular and histological study of prostate cancer: focus on PTEN

artículo científico publicado en 2015

Micromanaging the classification of colon cancer: the role of the microRNAome.

artículo científico publicado en 2011

Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines

artículo científico publicado en 2008

Molecular Dissection of Microsatellite Instable Colorectal Cancer ⬇️

artículo científico publicado el 1 de marzo de 2013

Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer

artículo científico publicado en 2016

Molecular Subtypes and the Evolution of Treatment Decisions in Metastatic Colorectal Cancer

artículo científico publicado en 2018

Molecular biology of testicular germ cell tumors.

artículo científico publicado en 2006

Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer

artículo científico publicado en 2014

Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009.

artículo científico publicado en 2010

Molecular predictors of response to chemotherapy in colorectal cancer

artículo científico publicado en 2011

Molecular prescreening to select patient population in early clinical trials

artículo científico publicado en 2012

Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials.

artículo científico publicado en 2012

Monoclonal antibodies in solid tumours

artículo científico publicado en 2010

Monoclonal antibodies in the treatment of advanced colorectal cancer.

artículo científico publicado en 2007

Multi-target angiokinase inhibitors to fight resistance

artículo científico publicado en 2014

Multicenter Randomized Phase II Clinical Trial Comparing Neoadjuvant Oxaliplatin, Capecitabine, and Preoperative Radiotherapy With or Without Cetuximab Followed by Total Mesorectal Excision in Patients With High-Risk Rectal Cancer (EXPERT-C)

article by Alice Dewdney et al published 10 May 2012 in Journal of Clinical Oncology

Multigene Assays to Improve Assessment of Recurrence Risk and Benefit From Chemotherapy in Early-Stage Colon Cancer: Has the Time Finally Arrived, or Are We Still Stage Locked?

scientific article published on 02 August 2010

Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies.

artículo científico publicado en 2016

New approaches and targets in advanced colorectal cancer.

artículo científico publicado en 2009

New approaches but the same flaws in the search for prognostic signatures

artículo científico publicado en 2014

New approaches in systemic treatment of advanced colorectal cancer: the molecular targets era.

artículo científico publicado en 2007

New approaches in the management of radioiodine-refractory thyroid cancer: the molecular targeted therapy era.

artículo científico publicado en 2010

New clinical trial designs in the era of precision medicine ⬇️

New drug development in digestive neuroendocrine tumors

artículo científico publicado en 2007

New drugs and new approaches in metastatic bladder cancer

artículo científico publicado en 2003

New players in cancer therapeutics: Focus on inhibitors of Mdmd2-p53 protein-protein interaction

New trends in epidermal growth factor receptor-directed monoclonal antibodies

artículo científico publicado en 2009

Novel targeted therapies in the treatment of gastric and esophageal cancer

artículo científico publicado en 2005

Novel targets for anticancer treatment development in colorectal cancer

artículo científico publicado en 2006

Novel targets in gastric and esophageal cancer

artículo científico publicado en 2006

O-024Circulating tumor DNA extended RAS mutational analysis as a surrogate of mutational status of tumor samples in metastatic colorectal cancer and its impact on patient selection for anti-EGFR therapy

Oncology and public health

article

Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma

artículo científico publicado en 2013

Optimal design of trials to demonstrate the utility of genomically-guided therapy: Putting Precision Cancer Medicine to the test

artículo científico

Optimal use of EGFR inhibitors: challenges, new drugs and future directions

Optimising translational oncology in clinical practice: strategies to accelerate progress in drug development.

artículo científico

Optimization of RAS/BRAF Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer.

artículo científico publicado en 2017

Overcoming Resistance to Anti-EGFR Therapy in Colorectal Cancer

artículo científico

Overview of biomarkers in metastatic colorectal cancer: tumour, blood and patient-related factors.

artículo científico

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

artículo científico publicado en 2004

Oxaliplatin-based chemotherapy in the management of colorectal cancer

artículo científico publicado en 2008

PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer

artículo científico publicado en 2016

PD-008Adding ramucirumab to second-line irinotecan, 5-fluorouracil and folinic acid (FOLFIRI) treatment for metastatic colorectal carcinoma (mCRC): resource utilization data from RAISE, a global, randomized, double-blind, multicenter phase 3 study

artículo científico publicado en 2016

PD-024Retrospective analysis of quality of life and early tumour shrinkage during first-line FOLFOX4 ± panitumumab in RAS wild-type metastatic colorectal carcinoma.

artículo científico publicado en 2016

PD-029Baseline carcinoembryonic antigen (CEA) as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma (mCRC) phase 3 trial.

artículo científico publicado en 2016

PELO negatively regulates HER receptor signalling and metastasis

artículo científico publicado en 2013

Pancreatic cancer heterogeneity and response to Mek inhibition

artículo científico publicado en 2017

Panitumumab - an effective long-term treatment for patients with metastatic colorectal cancer and wild-type KRAS status

artículo científico publicado en 2010

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

artículo científico publicado en 2013

Panitumumab: a summary of clinical development in colorectal cancer and future directions

artículo científico

Paracrine network: another step in the complexity of resistance to EGFR blockade?

artículo científico publicado en 2014

Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors

artículo científico publicado en 2012

Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies

artículo científico publicado en 2015

Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients

artículo científico

Pharmacodynamic Studies of Gefitinib in Tumor Biopsy Specimens From Patients With Advanced Gastric Carcinoma

artículo científico publicado en 2006

Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study.

artículo científico publicado en 2010

Pharmacokinetic and pharmacodynamic evaluation of aflibercept for the treatment of colorectal cancer

artículo científico

Pharmacokinetic/Pharmacodynamic Modeling for Drug Development in Oncology

artículo científico publicado en 2017

Phase I Clinical and Pharmacokinetic Study of Kahalalide F Administered Weekly as a 1-Hour Infusion to Patients with Advanced Solid Tumors

scientific article published on 01 February 2008

Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors

artículo científico publicado en 2015

Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors

artículo científico publicado en 2011

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors

artículo científico publicado en 2014

Phase I Study of the Selective Aurora A Kinase Inhibitor MLN8054 in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Pharmacodynamics

scientific article published on 19 August 2010

Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase

artículo científico publicado en 2010

Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors.

artículo científico publicado en 2013

Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors

artículo científico publicado en 2005

Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients

artículo científico publicado en 2008

Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors.

artículo científico publicado en 2012

Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors

artículo científico publicado en 2012

Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors

artículo científico publicado en 2010

Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer

artículo científico publicado en 2015

Phase I study of weekly kahalalide F as prolonged infusion in patients with advanced solid tumors

artículo científico publicado en 2013

Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors

artículo científico publicado en 2014

Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors

artículo científico publicado en 2015

Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer

artículo científico publicado en 2007

Phase II Study of Trabectedin in Pretreated Patients with Advanced Colorectal Cancer

scientific article published on 01 May 2007

Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer

artículo científico publicado en 2018

Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer.

artículo científico publicado en 2005

Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer

artículo científico publicado en 2013

Phase II randomized study of Plitidepsin (Aplidin), alone or in association with L-carnitine, in patients with unresectable advanced renal cell carcinoma

artículo científico publicado en 2009

Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients

artículo científico publicado en 1998

Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens

artículo científico publicado en 2013

Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer

artículo científico publicado en 2016

Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer

artículo científico publicado en 2007

Phase II trial of induction irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for unresectable, locally advanced gastric and oesophageal-gastric junction adenocarcinoma

artículo científico publicado en 2010

Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma

artículo científico publicado en 2009

Phase III Study of Capecitabine Plus Oxaliplatin Compared With Continuous-Infusion Fluorouracil Plus Oxaliplatin As First-Line Therapy in Metastatic Colorectal Cancer: Final Report of the Spanish Cooperative Group for the Treatment of Digestive Tumor

article

Phase III Trial of Capecitabine Plus Oxaliplatin As Adjuvant Therapy for Stage III Colon Cancer: A Planned Safety Analysis in 1,864 Patients

article

Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study

artículo científico publicado en 2018

Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors

artículo científico

Population pharmacokinetics and covariate analysis of Sym004, an antibody mixture against the epidermal growth factor receptor, in subjects with metastatic colorectal cancer and other solid tumors

scientific article published on 02 November 2019

Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas.

artículo científico publicado en 2016

Potential regional differences for the tolerability profiles of fluoropyrimidines

artículo científico publicado en 2008

Pragmatic issues in biomarker evaluation for targeted therapies in cancer

artículo científico publicado en 2014

Pre-operative chemoradiotherapy with UFT and Leucovorin in patients with advanced rectal cancer: a phase II study

artículo científico publicado en 2008

Preparing for the incoming wave of biosimilars in oncology

Prognosis and Therapeutic Implications for Emerging Colorectal Cancer Subtypes

Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial.

artículo científico publicado en 2016

Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer

artículo científico publicado en 2016

Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials

artículo científico

Prognostic and predictive roles for circulating biomarkers in gastrointestinal cancer

artículo científico publicado en 2011

Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer

artículo científico publicado en 2015

Prognostic impact of KRAS mutation in metastatic (met) pancreatic cancer patients (pts)

Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial.

artículo científico publicado en 2015

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset

artículo científico publicado en 2014

Progression-free survival: helpful biomarker or clinically meaningless end point?

artículo científico publicado en 2014

Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX.

artículo científico publicado en 2017

Proven efficacy, equitable access, and adjusted pricing of anti-cancer therapies: no ‘sweetheart’ solution

artículo científico publicado en 2015

Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trial

artículo científico publicado en 2017

Pushing the envelope in the mTOR pathway: the second generation of inhibitors

artículo científico publicado en 2011

QTWiST analysis of the RECOURSE trial of trifluridine/tipiracil in metastatic colorectal cancer.

artículo científico publicado en 2017

Quality of life during first-line FOLFOX4±panitumumab in RAS wild-type metastatic colorectal carcinoma: results from a randomised controlled trial.

artículo científico publicado en 2016

RAISE: A randomized, double-blind, multicenter phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab (RAM) or placebo (PBO) in patients (pts) with metastatic colorectal carcinoma (CRC) progressive during or follow

RE: Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration

artículo científico publicado en 2018

RHOA inactivation enhances Wnt signalling and promotes colorectal cancer.

artículo científico publicado en 2014

RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer

artículo científico publicado en 2022

Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy

artículo científico publicado en 2016

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

artículo científico publicado en 2014

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, doubl

artículo científico publicado en 2015

Randomized Phase 3 Study of Panitumumab With FOLFOX4 Compared to FOLFOX4 Alone as 1st-line Treatment (tx) for Metastatic Colorectal Cancer (mCRC): The PRIME Trial.

artículo científico publicado en 2010

Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.

artículo científico publicado en 2009

Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer

artículo científico publicado en 2014

Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: A Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study

article

Randomized trial of TAS-102 for refractory metastatic colorectal cancer

artículo científico publicado en 2015

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

artículo científico publicado en 2010

Rationale and Design for the LUME-Colon 1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Nintedanib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Colorectal Cancer Refractory t

artículo científico

Recent developments in anti-cancer agents targeting PI3K, Akt and mTORC1/2.

artículo científico publicado en 2011

Recomendaciones para la determinación de mutaciones de K-RAS en cáncer de colon

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

artículo científico publicado en 2013

Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial.

artículo científico publicado en 2015

Reply to M. Mo et al.

artículo científico publicado en 2017

Reply to the letter to the editor 'Can we trust burnout research?' by Bianchi et al.

artículo científico publicado en 2017

Reply to the letter to the editor 'Re-aligning the ASCO and ESMO clinical benefit frameworks or modern cancer therapies'.

artículo científico publicado en 2018

Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials

artículo científico publicado en 2017

SEOM clinical guidelines for the adjuvant treatment of colorectal cancer

artículo científico publicado en 2010

SEOM clinical guidelines for the treatment of pancreatic cancer

scientific article published on 01 August 2011

SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial

artículo científico

SPROUTY2 is a β-catenin and FOXO3a target gene indicative of poor prognosis in colon cancer

artículo científico publicado en 2013

Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer.

artículo científico publicado en 2015

Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors.

artículo científico publicado en 2015

Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer

artículo científico publicado en 2016

Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer

artículo científico publicado en 2016

Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients.

artículo científico publicado en 2016

Serial topoisomerase II expression in primary breast cancer and response to neoadjuvant anthracycline-based chemotherapy

artículo científico publicado en 2004

Short- and Long-Term Quality of Life and Bowel Function in Patients With MRI-Defined, High-Risk, Locally Advanced Rectal Cancer Treated With an Intensified Neoadjuvant Strategy in the Randomized Phase 2 EXPERT-C Trial

artículo científico publicado en 2015

Similarities and differences between the adjuvant oxaliplatin-based trials MOSAIC and NSABP C-07

Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial

artículo científico publicado en 2013

Sorafenib in metastatic thyroid cancer.

artículo científico publicado en 2012

Spectrum of Gene Mutations in Colorectal Cancer: Implications for Treatment

artículo científico publicado en 2016

Starting the Fight in the Tumor: Expert Recommendations for the Development of Human Intratumoral Immunotherapy (HIT-IT)

artículo científico publicado en 2018

Status of PI3K inhibition and biomarker development in cancer therapeutics

scientific article published on 27 August 2009

Strategies to design clinical studies to identify predictive biomarkers in cancer research.

artículo científico publicado en 2016

Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression

artículo científico publicado en 2016

Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal

artículo científico publicado en 2020

TGF-β signalling-related markers in cancer patients with bone metastasis

scientific article published on 01 March 2008

TGR Analysis in Phase I Clinical Trials--Letter

artículo científico publicado en 2014

TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial

artículo científico publicado en 2014

TTD consensus document on the diagnosis and management of exocrine pancreatic cancer.

artículo científico publicado en 2014

Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.

artículo científico publicado en 2015

Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer

artículo científico publicado en 2019

Targeted therapies for patients with advanced colorectal cancer: focus on cetuximab

Targeted therapies in thyroid cancer

artículo científico publicado en 2009

Targeted therapy in advanced colon cancer: the role of new therapies

artículo científico publicado en 2004

Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges

artículo científico publicado en 2017

Targeting the PI3K/Akt/mTOR Pathway - Beyond Rapalogs ⬇️

artículo científico publicado el 1 de noviembre de 2010

Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall?

artículo científico publicado en 2017

Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall?

artículo científico publicado en 2018

Tenth anniversary of bevacizumab in colorectal cancer: has it fulfilled its promise?

artículo científico publicado en 2014

The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer

artículo científico publicado en 2009

The Cancer Moonshot from a European perspective

artículo científico publicado en 2017

The European Cancer Patient's Bill of Rights, update and implementation 2016. ⬇️

artículo científico publicado en 2016

The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer

artículo científico publicado en 2016

The consensus molecular subtypes of colorectal cancer

artículo científico publicado en 2015

The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010

article

The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007.

artículo científico publicado en 2008

The evolution of our molecular understanding of colorectal cancer: what we are doing now, what the future holds, and how tumor profiling is just the beginning

artículo científico publicado en 2014

The expanding role of immunotherapy.

artículo científico publicado en 2017

The landscape of somatic copy-number alteration across human cancers

artículo científico publicado en 2010

The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008.

scientific article published on June 2009

The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006

article

The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies

artículo científico publicado en 2005

The neo-adjuvant, surgical and adjuvant treatment of gastric adenocarcinoma. Current expert opinion derived from the Seventh World Congress on Gastrointestinal Cancer, Barcelona, 2005

article

The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus

artículo científico publicado en 2012

The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.

artículo científico publicado en 2007

The role of salvage treatment in advanced colorectal cancer.

artículo científico publicado en 2008

The targeted therapy revolution in neuroendocrine tumors: in search of biomarkers for patient selection and response evaluation.

artículo científico publicado en 2013

Toward Efficient Trials in Colorectal Cancer: The ARCAD Clinical Trials Program

artículo científico publicado en 2009

Toward optimized front-line therapeutic strategies in patients with metastatic colorectal cancer--an expert review from the International Congress on Anti-Cancer Treatment (ICACT) 2009.

artículo científico publicado en 2010

Toxicity as a Biomarker of Efficacy of Molecular Targeted Therapies: Focus on EGFR and VEGF Inhibiting Anticancer Drugs ⬇️

artículo científico publicado el 1 de enero de 2011

Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors

scientific article published on 09 August 2011

Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM).

artículo científico publicado en 2010

Treatment recommendations for metastatic colorectal cancer

artículo científico publicado en 2011

Treatment-related mortality with aflibercept in cancer patients

artículo científico publicado en 2014

Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial

artículo científico publicado en 2018

Tumores neuroendocrinos: la era de las terapias dirigidas

artículo científico publicado en 2012

Understanding the predictive role of K-ras for epidermal growth factor receptor-targeted therapies in colorectal cancer.

artículo científico publicado en 2008

Unmet needs and challenges in gastric cancer: the way forward

artículo científico

Unsupervised analyses reveal molecular subtypes associated to prognosis and response to therapy in colorectal cancer

article published in 2014

Update on novel strategies to optimize cetuximab therapy in patients with metastatic colorectal cancer.

artículo científico publicado en 2008

Using pharmacokinetic and pharmacodynamic data in early decision making regarding drug development: a phase I clinical trial evaluating tyrosine kinase inhibitor, AEE788.

artículo científico publicado en 2012

Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

artículo científico publicado en 2015

What could Nintedanib (BIBF 1120), a triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options for patients with metastatic colorectal cancer?

artículo científico publicado en 2014

XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer

artículo científico publicado en 2004

mTOR Inhibition Beyond Rapalogs

mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer.

artículo científico publicado en 2017

nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of the MPACT trial

artículo científico publicado en 2017

nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.

artículo científico publicado en 2015

p95HER2-T cell bispecific antibody for breast cancer treatment

artículo científico publicado en 2018

β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer

artículo científico publicado en 2012

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda